Department of Clinical Research Center, Jinan Central Hospital Affiliated to Shandong University, Jinan, China.
Shanghai LingXian Medical Consulting CO., LTD, Jinan, China.
J Clin Pharm Ther. 2021 Jun;46(3):814-819. doi: 10.1111/jcpt.13361. Epub 2021 Jan 18.
Acarbose can efficiently block glucose absorption in the intestine as an alpha-glucosidase inhibitor. It is currently manufactured in several oral dosage forms, with the most common types being tablets and chewable tablets. The acarbose tablet (Glucobay , 50 mg, Bayer) package insert gives instructions for either directly swallowing or chewing then swallowing. This study compared the pharmacodynamic effects of a single formulation of acarbose tablets under these two different administration routes.
This randomized, crossover study enrolled 24 healthy subjects who were instructed to chew (C group) or swallow (S group) the acarbose tablet. Glucose levels were monitored in subjects for up to 4 h following administration of 75 g of sucrose to establish a baseline firstly, after which subjects in the C and S groups were administered 50- or 100- mg of acarbose along with 75 g of sucrose. Then, subjects entered a 1-week washout period before being crossed over to the alternate dosing route.
Compared with the S group, the C group had a lower maximum concentration of serum glucose (C ) and areas under the concentration-time curve (AUC , AUC ). In addition, the maximum reduction in serum glucose (ΔC ) and the reduction in the AUC (AUEC ) were both increased in the S group. This occurred at both the 50 mg and 100 mg dosages. These results indicate that fluctuations in blood glucose were lower following chewing of the acarbose tablet. Both administration routes exhibited similar safety and tolerance profiles.
In summary, chewing acarbose tablets appears to induce a superior glycaemic-controlling effect compared with swallowing them directly, at least with a single dose. It will be important to inform both clinicians and patients about these differences between the two administrations so that informed clinical decisions can be made, as numerous patients with diabetes are inclined to directly swallow acarbose tablets for convenience.
阿卡波糖作为一种α-葡萄糖苷酶抑制剂,可有效地在肠道中阻止葡萄糖吸收。它目前有几种口服剂型,最常见的是片剂和咀嚼片。阿卡波糖片(Glucobay,50mg,拜耳)的说明书指示可以直接吞服或咀嚼后吞服。本研究比较了这两种不同给药途径下单一配方阿卡波糖片的药效学效应。
这项随机、交叉研究纳入了 24 名健康受试者,他们被指示咀嚼(C 组)或吞服(S 组)阿卡波糖片。在给予 75g 蔗糖后,监测受试者的血糖水平长达 4 小时,首先建立基线,然后 C 组和 S 组受试者分别给予 50mg 或 100mg 阿卡波糖和 75g 蔗糖。然后,受试者进入 1 周洗脱期,然后交叉到另一种给药途径。
与 S 组相比,C 组的血清葡萄糖最大浓度(C )和浓度-时间曲线下面积(AUC,AUC )较低。此外,S 组的血清葡萄糖最大降低量(ΔC )和 AUC 降低量(AUEC )均增加。这两种剂量均如此。这表明咀嚼阿卡波糖片后血糖波动较低。两种给药途径均表现出相似的安全性和耐受性特征。
总之,与直接吞服相比,咀嚼阿卡波糖片似乎能更好地控制血糖,至少在单次剂量时如此。重要的是要将两种给药途径之间的这些差异告知临床医生和患者,以便做出明智的临床决策,因为许多糖尿病患者为了方便而倾向于直接吞服阿卡波糖片。